Christian Schmidkonz

Dr. Christian Schmidkonz


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 May 2018 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Closed access
PDF file
CSChristian Schmidkonz
Christian Schmidkonz
MCMichael Cordes
Michael Cordes
DSDaniela Schmidt
Daniela Schmidt
TBTobias Bäuerle
Tobias Bäuerle
TGTheresa Ida Goetz
Theresa Ida Goetz
PRPhilipp Ritt
Philipp Ritt

6 November 2017 in The Prostate
Verified
Journal Article
Open access
PDF file
CSChristian Schmidkonz
Christian Schmidkonz
CHClaudia Hollweg
Claudia Hollweg
MBMichael Beck
Michael Beck
JRJulia Reinfelder
Julia Reinfelder
TGTheresa I. Goetz
Theresa I. Goetz
PRPhilipp Ritt
Philipp Ritt
Background: 99mTc‐MIP‐1404 (Progenics Pharmaceuticals, Inc., New York, NY) is a novel, SPECT‐compatible 99mTc‐labeled PSMA inhibitor for the detection of prostate cancer. We present results of its clinical use in a cohort of 225 men with histologically confirmed prostate cancer referred for workup of biochemical relapse.Methods: From April 2013 to April 2017, 99mTc‐MIP1404‐scintigraphy was performed in 225 patients for workup of PSA biochemical relapse of prostate cancer. Whole‐body planar and SPECT/CT images of the lower abdomen and thorax were obtained 3‐4 h p.i. of 710 ± 64 MBq 99mTc‐MIP‐1404. Images were visually analyzed for presence and location of abnormal uptake. In addition, quantitative analysis of the SPECT/CT data was carried out on a subset of 125 patients. Follow‐up reports of subsequent therapeutic interventions were available for 59% (139) of all patients.Results: Tracer‐positive lesions were detected in 77% (174/225) of all patients. Detections occurred at the area of local recurrence in the prostate in 25% of patients (or a total of 56), with metastases in lymph nodes in 47% (105), bone in 27% (60), lung in 5% (12), and other locations in 2% (4) of patients. Detection rates were 90% at PSA levels ≥2 ng/mL and 54% below that threshold. Lesional SUVmax values were, on average, 32.2 ± 29.6 (0.8–142.2), and tumor‐to‐normal ratios 146.6 ± 160.5 (1.9–1482.4). The PSA level correlated significantly with total uptake of MIP‐1404 in tumors (P < 0.001). Furthermore, total tumor uptake was significantly higher in patients with Gleason scores ≥8 compared to those with Gleason scores ≤7 (P < 0.05). In patients with androgen deprivation therapy, the detection rate was significantly higher compared to patients without androgen deprivation therapy (86% vs 71%, P < 0.001). Based on 99mTc‐MIP‐1404‐imaging and other information, an interdisciplinary tumor board review recommended changes to treatment plans in 74% (104/139) of those patients for whom the necessary documentation was available.Conclusion: SPECT/CT with 99mTc‐labeled MIP‐1404 has a high probability in detecting PSMA‐positive lesions in patients with elevated PSA. Statistical analysis disclosed significant relationship between quantitative 99mTc‐MIP‐1404 uptake, PSA level, and Gleason score.

1 April 2018 in Clinical Nuclear Medicine
Verified
Journal Article
Closed access
CSChristian Schmidkonz
Christian Schmidkonz
MCMichael Cordes
Michael Cordes
MBMichael Beck
Michael Beck
TGTheresa Ida Msc Goetz
Theresa Ida Msc Goetz
DSDaniela Schmidt
Daniela Schmidt
PRPhilipp Ritt
Philipp Ritt
Background: 99mTc-MIP-1404 (Progenics Pharmaceuticals, Inc, New York, NY) is a novel ligand binding to prostate-specific membrane antigen suitable for SPECT. There are, as yet, no data concerning its use in whole-body primary staging and its interobserver variability in patients with prostate cancer (PC) prior to therapy. Methods: A search of our clinical database from April 2013 to May 2017 yielded 93 patients with histologically confirmed cancer in whom 99mTc-MIP-1404 SPECT/CT had been performed for primary whole-body staging before therapy. Whole-body planar and SPECT/CT images of the lower abdomen and thorax had been obtained 3 to 4 hours postinjection of 706 ± 72 MBq 99mTc-MIP-1404. Images were visually analyzed for extent and location of abnormal uptake by 2 experienced nuclear physicians. Interobserver agreement for detection of primary tumor and metastatic lesions was assessed. In addition, SUVs of prostate-specific membrane antigen–positive regions of the prostate were determined in all patients, and from these, a variable reflecting total tumor load in the prostate gland was calculated (TUprostate). Follow-up reports of subsequent therapeutic interventions were available in 52 (56%) of all patients with a median follow-up of 18 months. Results: In 90 (97%) of 93 patients, prostate uptake above background was detected as correlate of the histologically diagnosed PC. Forty-eight lymph node and 29 bone metastases were detected in 16 and 9 patients, respectively. In addition, 3 patients had disseminated bone metastases. No distant organ metastases were found. Interobserver agreement was high for the overall scan result (97%), as well as for the detection of the primary tumor (97%), of lymph node metastases (97%), and of bone metastases (99%). Recurrence of PC occurred in 5 patients in whom follow-up was available (10%). TUprostate was significantly higher in patients with Gleason scores of 8 or greater compared with patients with Gleason scores of 7 or less and at prostate-specific antigen (PSA) serum levels of 10 ng/mL or greater compared with PSA serum levels of 10 ng/mL or less. TUprostate of greater than 26 in the primary tumor predicted the occurrence of lymph node or bone metastases with a sensitivity of 82% and specificity of 76%. Conclusions: MIP-1404 SPECT/CT has a high accuracy and low interobserver variability in the diagnosis of PC and allows detection of lymph node and bone metastases in a significant proportion of as yet untreated PC patients. TUprostate is correlated with Gleason score and PSA serum concentration and allows prediction of the occurrence of lymph node and bone metastases with moderate accuracy at primary staging.

23 July 2019 in Annals of Nuclear Medicine
Verified
Journal Article
Closed access
PDF file
CSChristian Schmidkonz
Christian Schmidkonz
MCMichael Cordes
Michael Cordes
TGTheresa Ida Goetz
Theresa Ida Goetz
OPOlaf Prante
Olaf Prante
TKTorsten Kuwert
Torsten Kuwert
TBTobias Bäuerle
Tobias Bäuerle

1 September 2014 in European Journal of Radiology
Verified
Journal Article
Closed access
CSChristian Schmidkonz
Christian Schmidkonz
MMM. Marwan
M. Marwan
LKL. Klinghammer
L. Klinghammer
MMM. Mitschke
M. Mitschke
ASA. Schuhbaeck
A. Schuhbaeck
TPT. Pflederer
T. Pflederer

23 August 2021 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
MKManuela Krumbholz
Manuela Krumbholz
JEJohanna Eiblwieser
Johanna Eiblwieser
ARAndreas Ranft
Andreas Ranft
JZJakob Zierk
Jakob Zierk
CSChristian Schmidkonz
Christian Schmidkonz
MMMarkus Metzler
Markus Metzler
Purpose: We evaluated the predictive and prognostic value of circulating tumor DNA (ctDNA) in patients with Ewing sarcoma (EWS) treated in the EWING2008 trial. Experimental Design: Plasma samples from 102 patients with EWS enrolled in the EWING2008 trial were obtained before and during induction chemotherapy. Genomic EWSR1 fusion sequence spanning primers and probes were used for highly specific and sensitive quantification of the levels of ctDNA by digital droplet PCR. ctDNA levels were correlated to established clinical risk factors and outcome parameters. Results: Pretreatment ctDNA copy numbers were correlated with event-free and overall survival. The reduction in ctDNA levels below the detection limit was observed in most cases after only two blocks of vincristine, ifosfamide, doxorubicin, and etoposide (VIDE) induction chemotherapy. The persistence of ctDNA after two VIDE blocks was a strong predictor of poor outcomes. ctDNA levels correlated well with most established clinical risk factors; an inverse correlation was found only for the histologic response to induction therapy. ctDNA levels did not provide simple representations of tumor volume, but integrated information from various tumor characteristics represented an independent EWS tumor marker with predictive and prognostic value. Conclusions: ctDNA copy number in the plasma of patients with EWS is a quantifiable parameter for early risk stratification and can be used as a dynamic noninvasive biomarker for early prediction of treatment response and outcome of patients.